San Diego, California-based biotech Organovo Holdings (NASDAQ:ONVO) announced Tuesday that Eli Lilly (NYSE:LLY) has agreed to acquire its clinical drug development program targeting farnesoid X receptor (“FXR”) agonists.
Shares of the nano-cap biotech climbed ~203% in the premarket after the
